| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2851204 | American Heart Journal | 2006 | 6 Pages |
Abstract
PFO is a new marker of CHD progression and should be systematically assessed with routine contrast transthoracic echocardiography in patients with carcinoid syndrome to determine patients at high risk of CHD progression.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Nicolas MD, Emmanuel MD, PhD, Jean-François MD, Fabrice MD, Alban MD, Céline MD, Jean-Christian MD, FACC, Thierry MD, PhD, Pascal MD, Philippe MD, Olivier MD, FACC,